Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial Stats
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT01460706
Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
Overview
The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.
Sponsor
Turku University Hospital
Phase
Phase 2/3
Contacts
Heikki RI Minn, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR)
ClinicalTrials.gov
NCT01460706Drug / Compound
DOTATOC
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- SSTR2
Ligand Class: Peptides
Chelator: DOTA
Eligibility
Inclusion
- Language spoken: Finnish or Swedish
- Supratentorial recurrent glioma based on MRI and/or \[11C\]methionine PET imaging
- Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
- Supratentorial malignant glioma based on MRI imaging
- * Age: 18 to 70 years old
Exclusion
- Pregnant or lactating women
- * Any medical or psychiatric condition that compromises the subject´s ability to participate in the study
- Any other significant disease including liver or renal disease
Share your feedback
Help us improve your experience